NLS Pharmaceutics Ltd
For the period ended Dec 31, 2023. Filed May 15, 2024.
View on SEC.govAbout this filing
The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.
FY2023 · Filed May 15, 2024
NCEL$2.72-5.7%Stored close · as of Nov 6, 2026
Contents
Significant Changes
B. Significant Changes.
No significant change, other than as otherwise described in this annual report, has occurred in our operations since the date of our financial statements included in this annual report.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.